Terns Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, will present preclinical data on their novel allosteric BCR-ABL inhibitor, TERN-701, at the 30th European Hematology Association Congress (EHA25) in Milan, Italy. The event will take place from June 12-15, 2025. The presentation, scheduled for June 13, 2025, will highlight the potency of TERN-701 against various resistance mutations in chronic myeloid leukemia $(CML.UK)$, showcasing its potential clinical benefits over existing therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.